Danaher Corporation $DHR Shares Sold by Akre Capital Management LLC

Akre Capital Management LLC cut its stake in Danaher Corporation (NYSE:DHR) by 92.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 69,516 shares of the conglomerate’s stock after selling 805,315 shares during the period. Danaher accounts for 0.2% of Akre Capital Management LLC’s holdings, making the stock its 16th biggest holding. Akre Capital Management LLC’s holdings in Danaher were worth $15,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in Danaher in the third quarter worth $25,000. Elevated Capital Advisors LLC acquired a new stake in Danaher in the fourth quarter worth $26,000. WFA of San Diego LLC acquired a new stake in Danaher in the second quarter worth $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in Danaher in the third quarter worth $27,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Danaher in the fourth quarter worth $27,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Robert W. Baird decreased their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Guggenheim decreased their price target on Danaher from $275.00 to $235.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Evercore increased their price target on Danaher from $225.00 to $232.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 21st. TD Cowen decreased their price target on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, DZ Bank assumed coverage on Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $233.61.

Danaher Trading Down 0.5%

Shares of DHR stock opened at $179.95 on Friday. The stock has a 50-day simple moving average of $180.93 and a 200 day simple moving average of $204.78. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock has a market capitalization of $127.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.40 and a beta of 0.81. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the business posted $1.88 earnings per share. The company’s quarterly revenue was up 3.7% on a year-over-year basis. On average, sell-side analysts expect that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.9%. Danaher’s dividend payout ratio (DPR) is currently 30.95%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.